From targeting previously untreatable genes to developing smarter delivery systems, RNA innovation is redefining precision medicine, therapeutic reach, and market growth.
Frost & Sullivan’s latest analysis explores the fastest-growing RNA modalities, delivery breakthroughs, and strategic investment trends shaping the future of genetic medicine.
Will your strategy lead the next wave of transformation in RNA therapeutics?
Next-generation RNA modalities — Self-amplifying RNA (saRNA), circular RNA (circRNA), small-activating RNA (RNAa), microRNA (miRNA), aptamers — are unlocking targets beyond the reach of small molecules and biologics.
Partnership-driven approaches, licensing, and M&A are accelerating R&D, commercialization, and market expansion.
Tier I biopharma players are entering RNA through high-value alliances and acquisitions, raising the stakes for early innovators.
What’s Inside?
Fill in the form to access your exclusive copy now.
RNA Modalities and Delivery Technologies Reshaping Genetic Medicine
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on store.frost.com.
*$1,000 honorarium is subject to eligibility
